ironjustice

further review because of colinization in a heart value and
subsequent
serious life threatening infection. <<

I couldn't find this recall so I have no idea IF or WHY they would
have recalled / pulled it from the shelf.

The problem with ANY intervention is the FACT .. people .. are
involved.

People who don't wash their hands .. people who don't know or CARE
about infection ..

Sooo .. IF .. there was some sort of contamination .. then it was most
likely due to the stupidity of some PERSON .. somewhere ..

They probably used THIS other mouthwash to save some money ..

Bacteria Forces Recall of Mouthwash Used by Hospitals
By Peggy Peck, Executive Editor, MedPage Today
Published: May 07, 2008
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine.

ROCKVILLE, Md., May 7 -- A mouthwash commonly distributed to hospital
inpatients was recalled after testing positive for Burkholderia
cepacia, a bacteria that's often resistant to common antibiotics.

Hydrox Labs of Elgin, Illinois, which makes the product, issued a
voluntary recall after the CDC linked the mouthwash to B. cepacia.


The CDC had confirmed illnesses in one state among hospital patients
who had used the mouthwash, which is marketed as Cardinal Health
alcohol-free mouthwash.


The company said the mouthwash, packaged in 4 oz. bottles, was
distributed to hospitals, medical centers, and nursing homes
nationwide.


The recall includes all Cardinal Health mouthwash with the lot number
26228, which is stamped on the label on the side of the bottle, and
record number AG-210.


The FDA said B. cepacia poses little medical risk to healthy people,
but those who have certain health problems, including a weakened
immune system or chronic lung disease, particularly cystic fibrosis,
may be more susceptible to infections with the bacteria.


The effects of B. cepacia vary widely, ranging from no symptoms at
all, to serious respiratory infections, especially in patients with
cystic fibrosis.

----------------

Probiotic Mouthwash May Prevent Ventilator-Associated Pneumonia

By John Gever, Senior Editor, MedPage Today
Published: November 05, 2008
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of
Medicine, University of California, San Francisco Earn CME/CE credit
for reading medical news


LUND, Sweden, Nov. 5 -- A mouthwash containing the probiotic species
Lactobacillus plantarum 299 was as effective as chlorhexidine at
eliminating disease-causing pathogens from the upper respiratory
tract, researchers here said. Action Points
--------------------------------------------------------------------------------

Explain to interested patients that a mouthwash containing probiotic
bacteria was at least as effective as a standard antiseptic rinse in
reducing the emergence of pneumonia-causing pathogens in critically
ill patients.


Explain that the probiotic rinse is likely to have fewer side effects
than the chemical antiseptic.


Explain that the study involved relatively few patients and the
findings need to be confirmed in a larger study.
Potentially pathogenic bacteria were found in oropharyngeal samples
from eight of 23 mechanically ventilated patients after receiving the
probiotic rinse, compared with 13 of 21 patients treated with a
standard 0.1% chlorhexidine solution in a randomized trial, reported
Bengt Klarin, Ph.D., of Lund University, and colleagues online in
Critical Care.


Aspiration of pathogens such as Staphylococcus aureus and
Streptococcus pneumoniae lurking in the mouth and upper respiratory
tract is the chief cause of ventilator-associated pneumonia, the
researchers said.


"The present results indicate that Lactobacillus plantarum 299 might
be used as a component of oral care in intubated ICU patients," Dr.
Klarin and colleagues wrote.


"Besides offering a promising alternative to antiseptics like
chlorhexidine, a probiotic that adheres to the oral mucosa will be
able to counteract potentially pathogenic bacteria 24 hours a day,
which is superior to the fairly short-term effect of orally applied
chemical agents."


The probiotic rinse does not kill other organisms. Rather, it coats
mucosal surfaces with enough benign bacteria -- Lactobacillus
plantarum 299 is a component of normal oral flora -- to prevent
pathogens from forming colonies.


"Lactobacillus plantarum 299 might be able to lower the rate of
infection with such harmful microbes and in turn lead to fewer cases
of ventilator-associated pneumonia," Dr. Klarin and colleagues wrote.


But ventilator-associated pneumonia was too infrequent in the study --
one case in the probiotic group and three in control patients -- to
permit definitive conclusions.


The study protocol began with toothbrushing in all patients. Those in
the control group then had mucosal surfaces swabbed with the
chlorhexidine solution.


In the probiotic group, mucosal surfaces were swabbed with carbonated
water and then rinsed with the bacterial solution. Both procedures
were performed twice daily.


Cultures were taken from the oropharynx and trachea at baseline and
just before oral care procedures on days 2, 3, 5, 7, 10, 14, and 21.


The primary outcome measure was the detection of potentially
pathogenic bacteria not found in the baseline samples.


Findings in the tracheal samples were similar to the oropharyngeal
results.


Enterococci or Enterobacteriaceae species were found in seven tracheal
samples from the probiotic group and in nine from control patients.


A total of 26 different pathogens were found post-baseline in
patients, including S. aureus, airway bacteria, enteric organisms, and
fungi. No major differences were seen between groups in the
distributions among these categories.


The researchers noted that chlorhexidine is relatively inactive
against Gram-negative organisms and is also associated with
significant side effects, including irritation, tooth staining, and
occasional allergic reactions.


There were no adverse effects of the Lactobacillus probiotic in this
or earlier studies, the researchers said.


The researchers said their small sample was an important limitation of
the study. A larger trial is needed to confirm the results, they
said.

The study was funded by Region Skåne, Sweden, the Scandinavian Society
for Antimicrobial Chemotherapy Foundation, and Probi AB, which
produces Lactobacillus plantarum 299.
Two authors reported financial relationships with Probi in addition to
the research funding.

Additional source: Critical Care
Source reference:
Klarin B, et al "Use of the probiotic Lactobacillus plantarum 299 to
reduce pathogenic bacteria in the oropharynx of intubated patients: a
randomised controlled open pilot study" Critical Care 2008; DOI:
10.1186/cc7109.
Additional Emergency Medicine Coverage


Who loves ya.
Tom


Jesus Was A Vegetarian!
http://tinyurl.com/634q5a


Man Is A Herbivore!
http://tinyurl.com/4rq595


DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk